Displaying drugs 76 - 100 of 650 in total
Hydrocortisone probutate
Approved
Vet approved
Hydrocortisone valerate
Approved
Vet approved
Secukinumab
Secukinumab is a fully human monoclonal IgG1/κ antibody against interleukin-17A (IL-17A), a proinflammatory cytokine implicated in various chronic immune-mediated inflammatory disorders, such as plaque psoriasis. By blocking the actions of IL-17A, secukinumab works to inhibit the pro-inflammatory pathways that drive immune-mediated inflammatory disorders. Following its first global approval in Japan...
Approved
Matched Description: … Secukinumab is a fully human monoclonal IgG1/κ antibody against interleukin-17A (IL-17A), a proinflammatory …
Teprotumumab
Teprotumumab is a fully human IgG1 monoclonal antibody directed against the human insulin-like growth factor-1 receptor. Following a clinical trial in which its efficacy in the treatment of thyroid eye disease (TED) was assessed, it received "breakthrough therapy" designation from the FDA in 2016 and was approved by the FDA...
Approved
Investigational
Matched Description: … Teprotumumab is a fully human IgG1 monoclonal antibody directed against the human insulin-like growth …
Turoctocog alfa
Turoctocog alfa is a recombinant factor VIII (rFVIII) with a truncated B-domain made from the sequence coding for 10 amino acids from the N-terminus and 11 amino acids from the C-terminus of the naturally occurring B-domain. Turoctocog alfa is produced in Chinese hamster ovary (CHO) cells without addition of any...
Approved
Investigational
Matched Description: … molecules are cleaved at the C-terminal of the heavy chain (HC) at amino acid 720, and a monoclonal antibody …
Tralokinumab
Atopic dermatitis (AD) is an inflammatory skin disorder that causes skin inflammation, skin barrier dysfunction, and chronic pruritus. It is estimated to affect up to 20% of adults and children worldwide, and is frequently associated with other atopic conditions such as asthma or allergic rhinitis. While AD is a heterogenous...
Approved
Investigational
Matched Description: … [A242427]
Tralokinumab is a fully human IgG4 monoclonal antibody targeted against IL-13. …
Filgrastim
Filgrastim is a short-acting recombinant, non-pegylated human granulocyte colony-stimulating factor (G-CSF) analog produced by recombinant DNA technology. It has an amino acid sequence identical to endogenous G-CSF, but it is non-glycosylated unlike the endogenous G-CSF and has an N-terminal methionine added in the sequence for expression in E. Coli. Human...
Approved
Nuvaxovid
SARS-CoV-2, the causative agent of COVID-19, relies on the interaction between its trimeric spike (S) glycoprotein and angiotensin-converting enzyme 2 (hACE2) expressed on host cells in order to establish a productive infection in humans. Antibodies directed against the S protein are capable of blocking S-hACE2 interactions and neutralizing viral particles...
Approved
Investigational
Avacopan
Anti-neutrophil cytoplasmic (auto)antibody (ANCA)-associated vasculitis (AAV) is a rare (estimated incidence of 3 cases per 100,000 per year) form of "pauci-immune" systemic small-vessel vasculitis typified by the presence of ANCAs in the serum.[A240249, A240254, A227003] The full spectrum of AAV includes granulomatosis with polyangiitis (GPA), microscopic polyangiitis (MPA), eosinophilic granulomatosis...
Approved
Investigational
Matched Description: … Anti-neutrophil cytoplasmic (auto)antibody (ANCA)-associated vasculitis (AAV) is a rare (estimated incidence …
Lidocaine
Ever since its discovery and availability for sale and use in the late 1940s, lidocaine has become an exceptionally commonly used medication . In particular, lidocaine's principal mode of action in acting as a local anesthetic that numbs the sensations of tissues means the agent is indicated for facilitating local...
Approved
Vet approved
Matched Mixtures name: … ACAT SUK Kit (Accelerated COVID-19 Antibody Test Single Use Kit) …
Bevacizumab
There is a great deal of evidence indicating that vascular endothelial growth factor (VEGF) is important for the survival and proliferation of cancer cells.[A192939,A192837,A192891,A193275] VEGF plays an important role in angiogenesis, lymphangiogenesis, and tumor growth, which are all factors that contribute to its attractiveness as a therapeutic target for anti-cancer...
Approved
Investigational
Matched Synonyms: … Anti-VEGF monoclonal antibody ... Anti-VEGF Humanized Monoclonal Antibody …
Matched Description: … [A193272,A193275] It is a humanized monoclonal IgG antibody, and inhibits angiogenesis by binding and …
Matched Categories: … MONOCLONAL ANTIBODIES AND ANTIBODY DRUG CONJUGATES ... Vascular Endothelial Growth Factor-directed Antibody Interactions …
Matched Description: … [A193272,A193275] It is a humanized monoclonal IgG antibody, and inhibits angiogenesis by binding and …
Matched Categories: … MONOCLONAL ANTIBODIES AND ANTIBODY DRUG CONJUGATES ... Vascular Endothelial Growth Factor-directed Antibody Interactions …
Satralizumab
Satralizumab is a recombinant humanized monoclonal antibody targeted against human interleukin-6 (IL-6) receptors, similar to tocilizumab, which is produced in Chinese hamster ovary cells and based on an IgG2 framework. Satralizumab is used in the treatment of neuromyelitis optica spectrum disorder (NMOSD), a rare autoimmune inflammatory disorder of the central...
Approved
Matched Synonyms: … Humanised anti-IL-6 receptor monoclonal antibody …
Matched Description: … Satralizumab is a recombinant humanized monoclonal antibody targeted against human interleukin-6 (IL- ... Satralizumab was first approved for use in Canada in June 2020 for the treatment of AQP4 antibody-positive ... formulation developed by Chugai Pharmaceutical and Roche,[L15536] is uniquely formulated with "recycling antibody …
Matched Description: … Satralizumab is a recombinant humanized monoclonal antibody targeted against human interleukin-6 (IL- ... Satralizumab was first approved for use in Canada in June 2020 for the treatment of AQP4 antibody-positive ... formulation developed by Chugai Pharmaceutical and Roche,[L15536] is uniquely formulated with "recycling antibody …
Sutimlimab
Cold agglutinin disease (CAD) is a type of autoimmune hemolytic anemia (AIHA) in which autoantibodies directed against red blood cell surface antigens cause hemolysis at low (3-4°C) temperatures.[A245154,L40114] This cold subtype accounts for approximately 15-25% of all AIHA and is more common in the elderly.[A245159,L40114] In approximately 90% of cases,...
Approved
Investigational
Matched Synonyms: … Humanized IgG4 monoclonal antibody against total complement component 1, subcomponent s …
Matched Description: … Sutimlimab is a first-in-class humanized monoclonal antibody targeted at complement subunit C1s, which …
Matched Description: … Sutimlimab is a first-in-class humanized monoclonal antibody targeted at complement subunit C1s, which …
Mirvetuximab soravtansine
Mirvetuximab soravtansine-gynx (IMGN853) is an antibody-drug conjugate (ADC) formed by a monoclonal antibody (M9346A) that targets folate receptor alpha (FRα), covalently joined by a cleavable disulfide linker to the genotoxic compound DM4 (also known as soravtansine or ravtansine).[A254392,L43967] DM4 is conjugated to the antibody with a drug-to-antibody ratio of 3.5:1....
Approved
Investigational
Matched Synonyms: … Anti-FOLR1-monoclonal-antibody-maytansinoid-conjugate-IMGN-853 …
Matched Description: … [A254392,L43967] DM4 is conjugated to the antibody with a drug-to-antibody ratio of 3.5:1. ... Mirvetuximab soravtansine-gynx (IMGN853) is an antibody-drug conjugate (ADC) formed by a monoclonal antibody ... [A254387] The antibody component of mirvetuximab soravtansine-gynx binds to FRα, a receptor overexpressed …
Matched Categories: … Antibody-drug Conjugates …
Matched Description: … [A254392,L43967] DM4 is conjugated to the antibody with a drug-to-antibody ratio of 3.5:1. ... Mirvetuximab soravtansine-gynx (IMGN853) is an antibody-drug conjugate (ADC) formed by a monoclonal antibody ... [A254387] The antibody component of mirvetuximab soravtansine-gynx binds to FRα, a receptor overexpressed …
Matched Categories: … Antibody-drug Conjugates …
Digoxin Immune Fab (Ovine)
Digoxin Immune Fab is a sheep antibody (26-10) FAB fragment from sheep immunized with the digoxin derivative Digoxindicarboxymethylamine. It is used as an antidote for overdose of digoxin.
Approved
Matched Synonyms: … Digoxin-specific Antibody Fragments …
Matched Description: … Digoxin Immune Fab is a sheep antibody (26-10) FAB fragment from sheep immunized with the digoxin derivative …
Matched Description: … Digoxin Immune Fab is a sheep antibody (26-10) FAB fragment from sheep immunized with the digoxin derivative …
Dinutuximab
Dinutuximab is an IgG1 monoclonal human/mouse chimeric antibody against GD2, a disialoganglioside expressed on tumors of neuroectodermal origin, including human neuroblastoma and melanoma, with highly restricted expression on normal tissues. It is composed of the variable heavy- and light-chain regions of the murine anti-GD2 mAb 14.18 and the constant regions...
Approved
Investigational
Matched Synonyms: … Monoclonal antibody ch14.18 ... CHIMERIC ANTI-DISIALOGANGLIOSIDE (GD2) MONOCLONAL ANTIBODY (CH14.18/CHO) …
Matched Description: … Dinutuximab is an IgG1 monoclonal human/mouse chimeric antibody against GD2, a disialoganglioside expressed ... By binding to GD2, dinutiximab induces antibody-dependent cell-mediated cytotoxicity and complement-dependent …
Matched Categories: … Glycolipid Disialoganglioside-directed Antibody ... MONOCLONAL ANTIBODIES AND ANTIBODY DRUG CONJUGATES ... Glycolipid Disialoganglioside-directed Antibody Interactions …
Matched Description: … Dinutuximab is an IgG1 monoclonal human/mouse chimeric antibody against GD2, a disialoganglioside expressed ... By binding to GD2, dinutiximab induces antibody-dependent cell-mediated cytotoxicity and complement-dependent …
Matched Categories: … Glycolipid Disialoganglioside-directed Antibody ... MONOCLONAL ANTIBODIES AND ANTIBODY DRUG CONJUGATES ... Glycolipid Disialoganglioside-directed Antibody Interactions …
Elranatamab
Elranatamab is a bispecific B-cell maturation antigen (BCMA)-directed CD3 T-cell engager. It is a humanized immunoglobulin 2-alanine kappa antibody derived from two monoclonal antibodies (mAbs), an anti-BCMA mAb and an anti-CD3 mAb, each of which contributes one heavy chain and one light chain to drug structure. The resulting 4-chain bispecific...
Approved
Investigational
Matched Synonyms: … ANTI-CD3/ANTI-BCMA BISPECIFIC MONOCLONAL ANTIBODY PF-06863135 ... B-CELL MATURATION ANTIGEN (BCMA) CLUSTER OF DIFFERENTIATION 3 (CD3) BISPECIFIC MONOCLONAL ANTIBODY (MAB …
Matched Description: … It is a humanized immunoglobulin 2-alanine kappa antibody derived from two monoclonal antibodies (mAbs ... The resulting 4-chain bispecific antibody is covalently linked via five inter-chain disulfide bonds. …
Matched Description: … It is a humanized immunoglobulin 2-alanine kappa antibody derived from two monoclonal antibodies (mAbs ... The resulting 4-chain bispecific antibody is covalently linked via five inter-chain disulfide bonds. …
Polatuzumab vedotin
Polatuzumab vedotin is a CD79b-directed antibody-drug conjugate that delivers monomethyl auristatin E (MMAE), an anti-mitotic agent, to cancer cells. The drug consists of three components - a humanized immunoglobulin G1 (IgG1) monoclonal antibody specific for human CD79b (polatuzumab), MMAE, and protease-cleavable linker called maleimidocaproyl-valine-citrulline-p-aminobenzyloxycarbonyl (mc-vc-PAB) that covalently attaches MMAE to...
Approved
Investigational
Matched Description: … Polatuzumab vedotin is a CD79b-directed antibody-drug conjugate that delivers monomethyl auristatin E ... [L6658] The drug consists of three components - a humanized immunoglobulin G1 (IgG1) monoclonal antibody …
Matched Categories: … Antibody-drug Conjugates ... CD79b-directed Antibody–Drug Conjugates ... MONOCLONAL ANTIBODIES AND ANTIBODY DRUG CONJUGATES …
Matched Categories: … Antibody-drug Conjugates ... CD79b-directed Antibody–Drug Conjugates ... MONOCLONAL ANTIBODIES AND ANTIBODY DRUG CONJUGATES …
Elotuzumab
Elotuzumab is a humanized IgG1 (Immunoglobulin G) monoclonal antibody indicated in combination with lenalidomide and dexamethasone for the treatment of patients with multiple myeloma who have received one to three prior therapies. Elotuzumab targets SLAMF7, also known as Signaling Lymphocytic Activation Molecule Family member 7, a cell surface glycoprotein. Elotuzumab...
Approved
Matched Description: … Elotuzumab has a theoretical mass of 148.1 kDa for the intact antibody. ... Elotuzumab is a humanized IgG1 (Immunoglobulin G) monoclonal antibody indicated in combination with lenalidomide ... Elotuzumab consists of the complementary determining regions (CDR) of the mouse antibody, MuLuc63, grafted …
Matched Categories: … SLAMF7-directed Antibody Interactions ... SLAMF7-directed Immunostimulatory Antibody ... MONOCLONAL ANTIBODIES AND ANTIBODY DRUG CONJUGATES …
Matched Categories: … SLAMF7-directed Antibody Interactions ... SLAMF7-directed Immunostimulatory Antibody ... MONOCLONAL ANTIBODIES AND ANTIBODY DRUG CONJUGATES …
Denosumab
Denosumab is a novel, fully human IgG2 monoclonal antibody specific to receptor activator of nuclear factor kappa-B ligand (RANKL), suppresses bone resorption via inhibiting RANK-mediated activation of osteoclasts. It is the first and currently the only RANKL inhibitor approved to prevent osteoclast-mediated bone loss. Chemically, it consists of 2 heavy...
Approved
Matched Description: … Denosumab is a novel, fully human IgG2 monoclonal antibody specific to receptor activator of nuclear …
Galcanezumab
Galcanezumab is a humanized monoclonal antibody developed by Eli Lilly and Company against human calcitonin gene-related peptide (CGRP). Although several small-molecule CGRP receptor antagonists have been developed, humanized monoclonal antibodies like galcanezumab are specifically designed to selectively bind to CGRP entities with high potency. Given this target specificity, lack of...
Approved
Investigational
Matched Description: … Galcanezumab is a humanized monoclonal antibody developed by Eli Lilly and Company against human calcitonin …
Nirsevimab
Nirsevimab (MEDI8897) is a recombinant human immunoglobulin G1 kappa (IgG1ĸ) monoclonal antibody used to prevent respiratory syncytial virus (RSV) lower respiratory tract disease in neonates and infants. It binds to the prefusion conformation of the RSV F protein, a glycoprotein involved in the membrane fusion step of the viral entry...
Approved
Investigational
Matched Description: … Nirsevimab (MEDI8897) is a recombinant human immunoglobulin G1 kappa (IgG1ĸ) monoclonal antibody used ... [L44146,A254571] Compared to [palivizumab], another anti-RSV antibody, nirsevimab shows greater potency …
Matched Categories: … Respiratory Syncytial Virus Anti-F Protein Monoclonal Antibody …
Matched Categories: … Respiratory Syncytial Virus Anti-F Protein Monoclonal Antibody …
Atezolizumab
Atezolizumab is a humanized monoclonal antibody used to prevent the interaction of PD-L1 and PD-1, removing inhibition of immune responses seen in some cancers.[A18493,L7489] This medication is reserved for patients whose tumors express PD-L1, cannot receive platinum-based chemotherapy, or whose tumors do not respond to platinum-based chemotherapy. Atezolizumab was granted...
Approved
Investigational
Matched Description: … Atezolizumab is a humanized monoclonal antibody used to prevent the interaction of PD-L1 and PD-1, removing …
Matched Categories: … Programmed Death Receptor-1 Blocking Antibody ... MONOCLONAL ANTIBODIES AND ANTIBODY DRUG CONJUGATES ... Programmed Death Receptor-1-directed Antibody Interactions …
Matched Categories: … Programmed Death Receptor-1 Blocking Antibody ... MONOCLONAL ANTIBODIES AND ANTIBODY DRUG CONJUGATES ... Programmed Death Receptor-1-directed Antibody Interactions …
Displaying drugs 76 - 100 of 650 in total